Beam Therapeutics (BEAM)
(Delayed Data from NSDQ)
$32.17 USD
+2.36 (7.92%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $32.14 -0.03 (-0.09%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Earnings News For BEAM
-
Why Is Beam Therapeutics (BEAM) Up 10.1% Since Last Earnings Report?
-
Beam Therapeutics (BEAM) Q1 Loss Narrows, Revenues Miss
-
Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results
-
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Why Is Beam Therapeutics (BEAM) Down 22.1% Since Last Earnings Report?
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
-
Earnings Preview: Beam Therapeutics Inc. (BEAM) Q4 Earnings Expected to Decline
-
Why Is Beam Therapeutics Inc. (BEAM) Up 29.5% Since Last Earnings Report?
-
Beam Therapeutics (BEAM) Q3 Earnings & Revenues Beat Estimates
-
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
-
Beam Therapeutics Inc. (BEAM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
-
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
-
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
-
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Tops Revenue Estimates
-
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
-
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
-
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Tops Revenue Estimates
-
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
-
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Tops Revenue Estimates
-
Beam Therapeutics Inc. (BEAM) Reports Q1 Loss, Misses Revenue Estimates
-
Beam Therapeutics Inc. (BEAM) Reports Q4 Loss, Tops Revenue Estimates
-
Beam Therapeutics Inc. (BEAM) Reports Q3 Loss, Misses Revenue Estimates
-
Analysts Estimate Beam Therapeutics Inc. (BEAM) to Report a Decline in Earnings: What to Look Out for
-
Beam Therapeutics Inc. (BEAM) Reports Q2 Loss, Misses Revenue Estimates